QuantaMatrix

QuantaMatrix FCF/Debt

The Free Cash Flow to Debt Ratio of QuantaMatrix (317690.KQ) as of Nov 4, 2026 is -84.51 %. In the previous year, Free Cash Flow to Debt Ratio was -4,304.62 % — a change of -98.04% (higher).

FCF/Debt

-84.51 %

YoY

-98.04%

Last updated:

Free Cash Flow to Debt Ratio of QuantaMatrix is 2024 -84.51 % . Free Cash Flow to Debt Ratio of QuantaMatrix was 2023 -4,304.62 % . It decreases by -98.04% higher compared to the previous year.

The QuantaMatrix FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2017
-45.08 KRW
Jan 1, 2018
-29.06 KRW
Jan 1, 2019
-1,126.38 KRW
Jan 1, 2020
-1,137.83 KRW
Jan 1, 2021
-1,396.33 KRW
Jan 1, 2022
-2,101.69 KRW
Jan 1, 2023
-4,304.62 KRW
Jan 1, 2024
-84.51 KRW
The QuantaMatrix FCF/Debt history
YEARFCF/DebtYoY
-84.51 %-98.04%
-4,304.62 %+104.82%
-2,101.69 %+50.52%
-1,396.33 %+22.72%
-1,137.83 %+1.02%
-1,126.38 %+3,776.42%
-29.06 %-35.54%
-45.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

QuantaMatrix Stock analysis

What does QuantaMatrix do? QuantaMatrix Inc. generates revenue through the sale of its multi-diagnostic unique test platform, micro disc, antimicrobial susceptibility testing sepsis diagnostic equipment, molecular immunity diagnosis automation platform, rapid antituberculosis susceptibility testing equipment, and rapid antituberculosis susceptibility testing kits. The company also sells covid kits and conducts research and development for microbial diagnostic products. Its primary customers include healthcare facilities and laboratories requiring advanced diagnostic solutions for microbiological and molecular testing. The firm targets segments focused on infectious disease diagnostics, antimicrobial resistance testing, and rapid tuberculosis detection. The company's product portfolio emphasizes innovative diagnostic tools, with a strong focus on sepsis diagnostics and tuberculosis testing. By offering both equipment and kits, QuantaMatrix addresses diverse needs within the healthcare sector. The firm's research and development activities support continuous product enhancement and expansion into new diagnostic areas. QuantaMatrix Inc. serves the global market for diagnostic equipment, with particular emphasis on regions where infectious disease management is critical. Its products are designed to meet the demands of healthcare providers seeking efficient, accurate, and rapid diagnostic solutions. The company's strategy centers on leveraging its technological expertise to capture market share in specialized diagnostic segments. QuantaMatrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about QuantaMatrix stock

Free Cash Flow to Debt Ratio of QuantaMatrix is -84.51 % in 2024.

Free Cash Flow to Debt Ratio of QuantaMatrix changed from -4,304.62 % to -84.51 %, representing a -98.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio QuantaMatrix since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's QuantaMatrix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — QuantaMatrix

All Key Metrics — QuantaMatrix